指南与共识创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

β受体阻滞剂与创伤性脑损伤:系统评价、Meta分析及美国东部创伤外科协会指南

Beta-blockers and Traumatic Brain Injury: A Systematic Review, Meta-analysis, and Eastern Association for the Surgery of Trauma Guideline.
指南 / 共识 · Ann Surg · 2017-01-01
一句话结论成人急性创伤性脑损伤中,观察性研究显示院内使用β受体阻滞剂与住院死亡率降低相关(汇总OR 0.39),但证据质量极低,指南有条件推荐使用。

该指南基于系统评价与Meta分析,纳入9项研究、2005例接受β受体阻滞剂治疗的成人(≥16岁)钝性创伤TBI患者和6240例对照。院内使用β受体阻滞剂与住院死亡率降低相关(汇总OR 0.39,95%CI 0.27-0.56;I²=65%,P<0.00001)。纳入研究均未评估功能结局或生活质量,心肺不良事件罕有报告,未发现明确发表偏倚。指南有条件推荐成人急性TBI院内使用β受体阻滞剂,证据质量极低,并推荐进一步开展高质量试验。

要点

  • 成人(≥16岁)钝性创伤急性TBI患者,院内使用β受体阻滞剂与住院死亡率降低相关:汇总OR 0.39(95%CI 0.27-0.56)。
  • 该结论来自观察性研究,指南自评证据质量极低,推荐为有条件推荐。
  • 合并异质性I²=65%(P<0.00001),效应量需谨慎解读。
  • 纳入研究均未报告功能结局或生活质量,心肺不良事件罕有报告。
  • 指南推荐进一步开展高质量试验,以回答作用机制、亚组疗效、剂量-反应、疗程、功能结局和生活质量等问题。

适用人群与场景

  • 成人(年龄≥16岁)钝性创伤后因TBI入院并住院治疗的患者。

研究设计与关键结果

  • 系统评价与Meta分析(PROSPERO CRD42016048547),检索MEDLINE、EMBASE和CENTRAL数据库,纳入9项研究,共2005例接受β受体阻滞剂治疗的TBI患者和6240例对照。
  • 院内使用β受体阻滞剂与住院死亡率降低相关:汇总OR 0.39(95%CI 0.27-0.56;I²=65%,P<0.00001)。
  • 纳入研究均未评估功能结局或生活质量指标,心肺不良事件(如低血压、心动过缓、支气管痉挛和/或充血性心力衰竭)罕有报告。
  • 未发现明确的发表偏倚证据。

证据类型、等级与局限

  • 证据类型:系统评价、Meta分析及美国东部创伤外科协会(Eastern Association for the Surgery of Trauma)指南。
  • 证据质量:极低。
  • 推荐强度:有条件推荐院内使用β受体阻滞剂。
  • 局限:纳入研究均为观察性研究,证据质量极低;纳入研究均未评估功能结局或生活质量;心肺不良事件罕有报告。

对床旁实践的改变

  • 作者认为,在成人急性TBI中,观察性研究显示β受体阻滞剂带来显著的死亡率获益,但证据质量极低,有条件推荐院内使用β受体阻滞剂。
  • 作者推荐进一步开展高质量试验,以回答作用机制、亚组疗效、剂量-反应、疗程、功能结局及生活质量等问题。

指南或共识出处

  • Beta-blockers and Traumatic Brain Injury: A Systematic Review, Meta-analysis, and Eastern Association for the Surgery of Trauma Guideline(美国东部创伤外科协会,年份原文未写明)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To determine if beta-(β)-blockers improve outcomes after acute traumatic brain injury (TBI).

BACKGROUND: There have been no new inpatient pharmacologic therapies to improve TBI outcomes in a half-century. Treatment of TBI patients with β-blockers offers a potentially beneficial approach.

METHODS: Using MEDLINE, EMBASE, and CENTRAL databases, eligible articles for our systematic review and meta-analysis (PROSPERO CRD42016048547) included adult (age ≥ 16 years) blunt trauma patients admitted with TBI. The exposure of interest was β-blocker administration initiated during the hospitalization. Outcomes were mortality, functional measures, quality of life, cardiopulmonary morbidity (e.g., hypotension, bradycardia, bronchospasm, and/or congestive heart failure). Data were analyzed using a random-effects model, and represented by pooled odds ratio (OR) with 95% confidence intervals (CI) and statistical heterogeneity (I).

RESULTS: Data were extracted from 9 included studies encompassing 2005 unique TBI patients with β-blocker treatment and 6240 unique controls. Exposure to β-blockers after TBI was associated with a reduction of in-hospital mortality (pooled OR 0.39, 95% CI: 0.27-0.56; I = 65%, P < 0.00001). None of the included studies examined functional outcome or quality of life measures, and cardiopulmonary adverse events were rarely reported. No clear evidence of reporting bias was identified.

CONCLUSIONS: In adults with acute TBI, observational studies reveal a significant mortality advantage with β-blockers; however, quality of evidence is very low. We conditionally recommend the use of in-hospital β-blockers. However, we recommend further high-quality trials to answer questions about the mechanisms of action, effectiveness on subgroups, dose-response, length of therapy, functional outcome, and quality of life after β-blocker use for TBI.

来源:Ann Surg,查看原文。版权归原作者所有。

参考来源

  1. Alali AS, Mukherjee K, McCredie VA, et al. Beta-blockers and Traumatic Brain Injury: A Systematic Review, Meta-analysis, and Eastern Association for the Surgery of Trauma Guideline. Ann Surg. 2017. PMID: 28525411. doi:10.1097/SLA.0000000000002286

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。